2019
DOI: 10.3390/molecules24071389
|View full text |Cite
|
Sign up to set email alerts
|

A Cell-Based Strategy for Bioactivity Determination of Long-Acting Fc-Fusion Recombinant Human Growth Hormone

Abstract: The long-acting growth hormone (LAGH) is a promising alternative biopharmaceutical to treat growth hormone (GH) deficiency in children, and it was developed using a variety of technologies by several pharmaceutical companies. Most LAGH preparations, such as Fc fusion protein, are currently undergoing preclinical study and clinical trials. Accurate determination of bioactivity is critical for the efficacy of quality control systems of LAGH. The current in vivo rat weight gain assays used to determine the bioact… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
1
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(1 citation statement)
references
References 34 publications
0
1
0
Order By: Relevance
“…The present Special Issue comprises twelve full-length research articles covering the latest research trends and applications of pharmaceutical analytical chemistry. An interesting cell-based bioassay was proposed by the research group of C. Rao and J. Wang for the determination of the bioactivity of long-acting growth hormone as a potential alternative biopharmaceutical for the treatment of growth hormone deficiency [ 1 ]. The method is based on the usage of a luciferase reporter gene system, which is involved in the full-length human GH receptor (hGHR) and the SIE and GAS (SG) response element.…”
mentioning
confidence: 99%
“…The present Special Issue comprises twelve full-length research articles covering the latest research trends and applications of pharmaceutical analytical chemistry. An interesting cell-based bioassay was proposed by the research group of C. Rao and J. Wang for the determination of the bioactivity of long-acting growth hormone as a potential alternative biopharmaceutical for the treatment of growth hormone deficiency [ 1 ]. The method is based on the usage of a luciferase reporter gene system, which is involved in the full-length human GH receptor (hGHR) and the SIE and GAS (SG) response element.…”
mentioning
confidence: 99%